Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Enovis (ENOV) stock in plain English

Free brief · no signupStart here
ENOVPublished Nov 19, 2026
Enovis Corp
Healthcare · Medical Devices
Sells surgical joint implants and orthopedic braces directly to hospitals and rehabilitation clinics. Provides physical therapy equipment alongside digital surgical guidance systems.
Assets:
Extensive surgical portfolioincludes hips, knees, and extremities
Global manufacturing networkfacilities across North America, Europe, and Asia
Over 9,000 employeessupporting clinical sales and medical device production worldwide
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

40
OPS ScoreOperating finances
Latest quote
-3.21%$26.23
$1.51B
n/a (loss)
$2.29B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ENOV. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Enovis (ENOV) do?

Enovis Corp (ENOV) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Sells surgical joint implants and orthopedic braces directly to hospitals and rehabilitation clinics. Provides physical therapy equipment alongside digital surgical guidance systems. Manufactures orthopedic braces and reconstructive surgical implants, covering patient care from prevention through. It is worth $1.51B on the market and sold $2.29B over the last year.

Market cap
$1.51B
P/E ratio
None (reported a loss)
Annual sales
$2.29B
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 19, 2026

Brands and businesses behind ENOV

  • DonJoy: Manufactures rigid knee braces and pain management supports sold to injured athletes and rehabilitation patients.
  • Aircast: Sells pneumatic walking boots and cold therapy ankle braces for sprains and post-surgical recovery.
  • LimaCorporate: Produces 3D-printed titanium joint replacements and extremities implants purchased by orthopedic surgery centers.
  • Chattanooga: Sells ultrasound, electrotherapy, and traction treatment devices directly to physical therapy practices worldwide.
  • Exos: Makes thermoformable splints and casts that replace traditional plaster for fracture management.

ENOV’s flags, in plain English

Each flag is a number from Enovis’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Stupid Cash

Can pay this year's bills 2.2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 53.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Burning Cash

Losing money, profit margin of -22.8%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about ENOV

How big is Enovis?

Enovis’ market cap is $1.51B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.29B: what customers paid the company over the last year, before any costs.

What is ENOV’s P/E ratio?

ENOV has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with ENOV?

Enovis carries substantial long-term debt taken on to finance acquisitions like LimaCorporate. That is one risk on Enovis’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Enovis’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ENOV’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card